Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
AssigneeThe Regents of the University of California
InventorsBin Liu, James D. Marks
Life of this patent
Estimating the term…
Abstract
This invention provides a method that allows selection of antibodies against cells (e.g., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens.
Claims12
A method of inhibiting the growth and/or proliferation of a prostate cancer cell, said method comprising contacting said cell with a chimeric moiety comprising an antibody attached to an anti-cancer drug or a radionuclide, where said antibody comprises the three variable heavy complementarity determining regions (VH CDRs) and the three variable light complementarity determining regions (VL CDRs) of the UA20 antibody (SEQ ID NO:8).
Dependencies are inferred from the claim text.